Day: March 27, 2020

Newport Beach, Calif., March 27, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) (“DPW” or the “Company”), a diversified holding company announced today that, due to the emerging public health impact of the coronavirus (COVID-19) pandemic, the location of DPW’s special meeting of stockholders that was originally scheduled to be held on Tuesday, March 31, 2020 at 9:00 a.m. PT at the Hyatt Regency Hotel Newport Beach, located at 1107 Jamboree Road, Newport Beach, CA 92660 (the “Special Meeting”) has been changed and will be held in a virtual meeting format only on April 30, 2020 at 9:00 a.m. PT.The Special Meeting will be held for the following purposes:To approve the issuance of shares of the Corporation’s Class A common stock, par value $0.001 per share (“Common Stock”) to Esousa Holdings LLC (“Esousa”), in accordance...

 Hamilton, Bermuda, March 27, 2020Dear Shareholders,We would like to advice you that Jim Kelly has been appointed Vice Chairman of Nordic American Tankers (NAT), following the sad passing of Mr. Andreas Ove Ugland who had this positon in the past.Herbjørn HanssonChairman & CEONordic American Tankers Ltd.                                                           www.nat.bm Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which...

Sjá meðfylgjandi ársreikning GAMMA: Méllon.ViðhengiGAMMA_Ársreikningur Méllon_31.12.2019 – FINAL

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the suggestion of the U.S. Food and Drug Administration (FDA), the Company filed another round of modifications to its IND and protocol for a Phase 2 clinical trial with leronlimab (PRO 140). In addition, the FDA suggested the Company file a second randomized protocol for all COVID-19 patients in severe condition, so as to preclude each physician from filing an emergency IND for every patient to be treated with leronlimab.The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of...

New York, NY – (March 25, 2020): United Thinkers, a New-York based commercial open-source Payment Management Software company, has updated its evergreen white paper for those, who want to provide payment gateway services, in order to harmonize the document with the present-day merchant services industry realities. United Thinkers updated the white paper, that sets the guidelines for prospective payment gateway providers. The white paper is intended to help those who want to have their own payment gateway avoid common mistakes and smoothly complete the process. Payment gateway selection is a tedious and time-consuming routine, and many businesses end up unsatisfied with the gateway they have been choosing so carefully. That is why, people often prefer to build their own payment gateway solution rather than look for the best gateway option...

Singapore, April 10, 2019 — Blockchain App Factory, a leading company in the domain of customizable white label cryptocurrency exchange development, offers solutions to the liquidity problem that is detrimental to the growth of the crypto trading sector. For long, cryptocurrency exchanges have faced issues with enabling efficient liquidity options that helps traders convert assets from cryptocurrency to fiat currency and vice versa. “The interest in cryptocurrency has grown at a fast rate over the past couple of years. However, trading outlets have not been able to capitalize on this popularity owing to factors such as accessibility, high fees and low liquidity,” a spokesperson from Blockchain App Factory summarized. Blockchain App Factory focuses on creating a conducive environment for trading by developing white label...

InformationThe nomination committee’s reasoned proposals to the annual general meeting 2020The Nomination Committee composed of Daniel Nyvang Mariussen (chairman), appointed by Bumble Ventures and Better Partners, Martin Jonasson, appointed by Andra AP Fonden, Michael Knutsson, appointed by Knutsson Holdings, and Jens Bager, chairman of the board of directors, Better Collective, presents the following proposals:that Andreas Nielsen, Partner at Bruun & Hjejle, is appointed chairman of the general meeting,that the board of directors will be comprised of six (6) board members,that the following members of the board of directors shall be re-elected, Jens Bager (also to be reelected as chairman of the board of directors), Klaus Holse, Leif Nørgaard, Søren Jørgensen and Petra von Rohr. Furthermore, the Nomination Committee proposes that...

HANGZHOU, China, March 27, 2020 (GLOBE NEWSWIRE) — UTStarcom (“UT” or “the Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today reported its unaudited financial results for the fourth quarter and full year ended December 31, 2019, and provided a business update.Business UpdateQ4 Revenue Met Expectations.  Fourth quarter revenue of $14.2 million was at the high end of the Company’s guidance range of $10 to $15 million.  The net loss for the quarter was attributable to foreign currency losses and a slight operating loss.CEO Leave of Absence.  As announced on March 16, 2020, the Company’s Chief Executive Officer (CEO) Mr. Tim Ti has taken a temporary leave of absence due to health reasons (unrelated to the COVID-19 virus).  The Company’s Board of Directors appointed UT’s Senior Vice President of Sales...

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the three-day results post-leronlimab treatment of the first four patients under an Emergency Investigational New Drug (EIND) granted by the U.S. Food and Drug Administration (FDA).  A total of seven patients have been enrolled thus far under EIND in the same leading medical center in the New York City area.The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).  Leronlimab is believed to provide therapeutic benefit...